Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RFX3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA557366
Description
Immunogen sequence: QYMAMRQQPM QQKQRYKPMQ KVDGVADGFT GSGQQTGTSV EQTVIAQSQH HQQFLDASRA LPEFGEVEIS SLPDGTTFED IKSLQSLYRE HCEAILDVVV NLQFSLIEKL WQTFWRYSPS TPTDGTTITE SSNLSE Highest antigen sequence identity to the following orthologs: Mouse - 99%, Rat - 100%.
This gene is a member of the regulatory factor X gene family, which encodes transcription factors that contain a highly-conserved winged helix DNA binding domain. The protein encoded by this gene is structurally related to regulatory factors X1, X2, X4, and X5. It is a transcriptional activator that can bind DNA as a monomer or as a heterodimer with other RFX family members. Two transcript variants encoding different isoforms have been described for this gene, and at least one of the variants utilizes alternative polyadenylation signals.
Specifications
RFX3 | |
Polyclonal | |
Unconjugated | |
RFX3 | |
bA32F11.1; C230093O12Rik; DNA binding protein RFX3; MRFX3; Regulatory factor X 3; regulatory factor X, 3 (influences HLA class II expression); regulatory factor X3; Rfx2; RFX3; Transcription factor RFX3 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
5991 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
0.08 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
P48380 | |
RFX3 | |
Recombinant protein corresponding to Human RFX3. Recombinant protein control fragment (Product #RP-89300). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction